identif
novel
cytotox
lymphocyt
ctl
epitop
import
analysi
involv
cell
mycobacterium
tuberculosi
infect
well
develop
peptid
vaccin
studi
novel
ctl
epitop
region
differ
encod
antigen
identifi
epitop
predict
revers
immunolog
approach
liasnvagv
identifi
rel
strong
bind
affin
stabil
toward
hlaa
molecul
peripher
blood
mononuclear
cell
puls
peptid
abl
releas
healthi
donor
hlaa
purifi
protein
deriv
cytotox
assay
vitro
vivo
induc
ctl
specif
lyse
target
cell
therefor
epitop
could
provid
subunit
compon
design
vaccin
mycobacterium
tuberculosi
cellular
immun
essenti
fight
infect
caus
intracellular
pathogen
includ
tuberculosi
epitopespecif
tuberculosi
reactiv
cell
reportedli
present
larg
number
circul
ppd
purifi
protein
deriv
posit
individu
patient
activ
tb
indic
import
cell
immun
tuberculosi
also
emphas
vaccin
activ
cell
subset
could
effect
tool
control
tuberculosi
bottleneck
develop
peptid
vaccin
identif
ctl
epitop
mani
major
histocompat
complex
class
irestrict
ctl
epitop
continu
identifi
antigen
tuberculosi
genom
compar
analysi
reveal
sever
genom
region
tuberculosi
delet
bcg
mycobacteria
delet
region
rd
predict
encod
protein
overcom
crossreact
bcg
vaccin
tuberculosi
great
effort
made
identifi
antigen
miss
bcg
present
tuberculosi
encod
gene
rd
region
region
encod
protein
novel
immunodomin
antigen
tuberculosi
induc
humor
cellular
immun
respons
mice
bcg
genom
nucleotid
sequenc
ctermin
fragment
absent
howev
ntermin
fragment
conserv
fusion
protein
ntermin
fragment
fusion
protein
annot
bcg
pasteur
genom
express
tuberculosi
exponenti
growth
vitro
recogn
patient
pulmonari
extrapulmonari
tb
therefor
deduc
might
contain
cell
epitop
high
preval
supertyp
chines
subject
perform
revers
immunolog
approach
search
potenti
hlaa
epitop
identifi
novel
cytotox
lymphocyt
epitop
vitro
vivo
assay
peripher
heparin
venou
blood
sampl
obtain
seven
healthi
donor
hlaa
ppd
ethic
committe
zhengzhou
univers
approv
sampl
collect
human
tapdefici
cell
line
transfect
hlaa
cultur
imdm
supplement
fb
incub
humidifi
atmospher
contain
co
cell
line
provid
professor
yuzhang
wu
third
militari
medic
univers
china
internet
servic
bima
syfpeithi
netctl
use
epitop
predict
nativ
peptid
predict
score
rank
top
three
least
two
predict
tool
select
standard
solid
phase
fmoc
strategi
use
predict
peptid
synthesi
product
purifi
puriti
rphplc
sequenc
confirm
esim
posit
control
hlaa
bind
assay
iligetiki
use
ia
brestrict
hbv
core
antigenderiv
th
epitop
sequenc
tppayrppnapil
use
helper
epitop
vivo
assay
b
transgen
mice
kindli
suppli
professor
xuetao
cao
second
militari
medic
univers
china
mice
bred
maintain
specif
pathogenfre
facil
present
experi
mice
week
age
use
determin
bind
properti
candid
peptid
toward
hlaa
molecul
upregul
peptideinduc
hlaa
molecul
cell
examin
accord
previous
describ
protocol
briefli
cell
incub
peptid
serumfre
imdm
contain
human
sigma
st
loui
mo
usa
c
hr
cell
wash
twice
incub
monoclon
antibodi
wash
three
time
cell
treat
fluorescein
isothiocyanatelabel
goat
igg
antimous
immunoglobulin
sigma
cell
harvest
analyz
facscalibur
flow
cytomet
becton
dickinson
spark
md
usa
fi
calcul
follow
formula
fi
mfi
sampl
mfi
background
mfi
background
mfi
background
repres
valu
without
peptid
peptidehlaa
complex
stabil
assay
cell
incub
peptid
serumfre
imdm
medium
contain
c
hr
cell
wash
remov
free
peptid
incub
brefeldina
hr
cell
wash
twice
stain
analyz
flow
cytomet
dc
defin
estim
time
requir
reduct
mfi
valu
record
time
induct
ctl
vitro
perform
accord
procedur
previous
describ
pbmc
separ
peripher
blood
hlaa
ppd
healthi
donor
ficollhypaqu
densiti
gradient
centrifug
cell
stimul
everi
day
peptid
imdm
medium
supplement
fb
third
day
first
stimul
subsequ
stimul
human
recombin
uml
ad
cell
employ
experi
day
three
group
b
transgen
mice
four
mice
group
immun
base
tail
variou
peptid
th
epitop
prepar
ifa
day
one
group
mice
receiv
ifa
contain
pb
anoth
th
peptid
use
neg
control
day
spleen
lymphocyt
cell
ml
separ
restimul
peptid
vitro
day
restimul
specif
cytotox
assay
employ
commerci
kit
human
precoat
elispot
kit
dakew
biotech
shenzhen
china
use
elispot
assay
effector
cell
stimul
cell
peptidepuls
cell
cocultur
micropl
coat
antibodi
specif
human
incub
c
hr
cell
remov
plate
process
number
spot
determin
automat
use
computerassist
spot
analyz
dakew
biotech
nonradioact
method
assay
cytotox
lymphocyt
employ
base
measur
ldh
releas
target
cell
grade
e
ratio
ctl
pbmc
healthi
donor
ctl
spleen
lymphocyt
transgen
mice
briefli
cell
load
peptid
c
hr
use
target
cell
target
cell
well
cocultur
variou
number
effector
cell
c
hr
percentag
specif
lysi
target
cell
determin
accord
follow
equat
percentag
specif
lysi
experiment
releas
effector
spontan
releas
target
spontan
releas
target
maximum
releas
target
spontan
releas
data
express
mean
sd
signific
analyz
one
way
ananlysi
varianc
p
consid
signific
statist
analys
perform
spss
first
select
three
candid
peptid
deriv
protein
optim
predict
score
predict
score
rank
top
three
least
two
predict
tool
toward
hlaa
molecul
studi
tabl
peptid
involv
ntermin
fragment
conserv
virul
strain
bovi
bcg
confirm
molecular
weight
peptid
esim
tabl
evalu
bind
affin
peptid
hlaa
molecul
stabil
peptidehlaa
complex
vitro
use
bind
affin
stabil
assay
label
affin
stabil
capac
nonam
peptid
fi
dc
respect
tabl
three
candid
liasnvagv
show
highest
bind
affin
stabil
dc
hr
toward
hlaa
therefor
chose
peptid
studi
test
elispot
assay
whether
peptidespecif
ctl
caus
releas
expand
pbmc
hlaa
ppd
individu
challeng
peptid
vitro
stimul
pbmc
seven
donor
use
pb
pha
neg
posit
control
respect
induc
pbmc
two
donor
produc
fig
pha
posit
control
elicit
product
pbmc
seven
donor
pb
elicit
product
partial
data
shown
addit
perform
releas
assay
carri
ldh
releas
assay
test
cytotox
activ
ctl
induc
investig
whether
trigger
specif
function
ctl
respons
lyse
target
cell
pbmc
donor
isol
stimul
vitro
measur
cytotox
activ
respond
cell
ldh
cytotox
assay
peptideload
cell
serv
target
cell
shown
fig
gener
peptidespecif
cell
specif
lyse
peptidepuls
cell
percentag
specif
lysi
e
ratio
prove
ctl
induc
lyse
target
cell
vitro
howev
vivo
environ
complex
import
determin
whether
peptid
natur
process
present
induc
peptidespecif
ctl
vivo
therefor
use
b
transgen
mice
vivo
anim
model
shown
fig
percentag
specif
lysi
increas
e
ratio
although
mice
immun
epitop
bodi
weight
significantli
differ
control
group
mice
indic
might
low
toxic
data
shown
vivo
result
suggest
natur
process
present
induc
potent
peptidespecif
ctl
respons
vivo
tradit
identif
cell
epitop
requir
synthesi
overlap
peptid
span
entir
length
protein
follow
experiment
assay
vitro
intracellular
cytokin
stain
peptid
assess
cell
activ
method
econom
viabl
singl
protein
pathogen
consist
sever
protein
therefor
research
develop
altern
comput
approach
predict
cell
epitop
significantli
decreas
experiment
burden
previous
associ
epitop
identif
practic
use
one
comput
algorithm
c
societi
blackwel
publish
asia
pti
ltd
mice
inject
subcutan
candid
peptid
emulsifi
ifa
presenc
ia
b
restrict
hbvcore
th
epitop
day
mice
inject
ifa
contain
pb
helper
epitop
use
neg
control
day
anim
kill
spleen
lymphocyt
restimul
vitro
peptid
addit
day
amount
ldh
releas
measur
data
repres
mean
sd
repres
p
vs
th
epitop
group
n
predict
ctl
epitop
may
lead
larg
number
fals
posit
fals
neg
recent
comprehens
valid
use
data
sever
differ
type
predict
softwar
prove
accur
consider
reduc
cost
epitop
discoveri
howev
differ
predict
tool
base
differ
comput
algorithm
predict
differ
choos
care
miss
immunodomin
epitop
therefor
studi
chose
three
predict
tool
base
differ
comput
algorithm
achiev
result
accur
one
approach
find
new
gener
effect
safe
vaccin
epitopebas
dna
vaccin
enabl
focus
immun
respons
import
highli
conserv
epitop
approach
provid
opportun
use
specif
epitop
shift
immun
system
toward
immun
respons
elimin
unwant
respons
addit
ctl
epitopebas
immun
advantag
elicit
immun
respons
protect
epitop
avoid
epitop
drift
tuberculosi
infect
studi
tuberculosi
human
shown
induct
broad
tcell
mediat
immun
tuberculosi
type
cytokin
includ
could
essenti
tb
vaccin
design
vaccin
base
ctl
epitop
repres
logic
approach
gener
effect
cellular
immun
prophylact
therapeut
set
multipl
epitop
incorpor
vaccin
design
goal
induc
broadli
reactiv
respons
multipl
ctl
clone
direct
differ
epitop
multictl
epitop
dna
vaccin
report
induc
broad
ctl
respons
hiv
hbv
sever
acut
respiratori
syndrom
coronaviru
other
wherea
epitopebas
vaccin
limit
respect
hla
polymorph
popul
coverag
use
supertyperestrict
epitop
provid
mean
address
problem
conclus
identifi
novel
cell
epitop
deriv
result
show
liasnvagv
could
serv
candid
peptid
vaccin
tuberculosi
